Stapled Peptides That Bind DNA: An Emerging Approach to Controlling Gene Activity | Research

The takeaway

This review examines the small but promising field of DNA-binding stapled peptides, which could offer sequence-specific gene regulation that small molecules currently cannot achieve.

1 stapled peptide in clinical trials
For protein-protein interaction disruption — DNA-binding stapled peptides are far behind but could follow a similar development path

What the researchers found

The review catalogues all known DNA-binding stapled peptides in the literature, noting that despite the strong parallel to protein-protein interaction (PPI) disrupting stapled peptides, very few DNA-binding examples exist. Key observations include:

Stapled peptides have proven highly successful at mimicking α-helical protein surfaces to disrupt PPIs, with at least one example in clinical trials. Since DNA-protein interactions are also frequently mediated by α-helices — particularly in transcription factors — the same stapling approach should theoretically apply to DNA binding. Unlike DNA-binding small molecules, which typically lack sequence selectivity, stapled peptides modeled on transcription factor helices could achieve both high affinity and high DNA sequence selectivity.

Why it matters

Controlling which genes are active is central to treating cancer, genetic diseases, and many other conditions. Current small molecule approaches to targeting DNA lack the precision to distinguish between similar DNA sequences, leading to off-target effects. If stapled peptides can be designed to bind specific DNA sequences with the same selectivity as natural transcription factors, they could become a powerful new class of therapeutics for diseases driven by aberrant gene expression.

How the study worked

This is a review article that comprehensively examines all published examples of DNA-binding stapled peptides. The authors compare the design concepts used in DNA-binding stapled peptides to those established for protein-protein interaction disrupting stapled peptides, identifying trends and design principles from the limited existing literature.

What this study cannot tell us

As a review, this paper synthesizes existing work rather than presenting new experimental data. The field itself is very young with very few published examples of DNA-binding stapled peptides, making it difficult to draw strong generalizable conclusions. The review does not address practical challenges like cellular delivery, metabolic stability, or in vivo efficacy of DNA-binding stapled peptides. The comparison to PPI-disrupting stapled peptides, while logical, may oversimplify the unique challenges of DNA recognition.

How to read the evidence

This is a review article that surveys the existing literature rather than presenting original experimental data. It provides a useful synthesis of the field but does not contribute new evidence. The underlying studies reviewed vary in their evidence quality.

When this study was published

Published in 2023, this review captures the current state of a young and rapidly evolving field. New DNA-binding stapled peptide designs are likely emerging as the technology matures.

The bigger picture

Stapled peptides represent one of the most active areas of peptide drug development. While most effort has focused on disrupting protein-protein interactions (like the p53-MDM2 interaction in cancer), this review highlights an underexplored frontier: using stapled peptides to directly target DNA. This could complement existing gene regulation strategies like antisense oligonucleotides, siRNA, and CRISPR by offering a protein-mimetic approach to transcriptional control.

Questions still open

What are the key design differences between stapled peptides that bind DNA versus those that disrupt protein-protein interactions?
Can DNA-binding stapled peptides achieve the same level of sequence specificity as natural transcription factors?
Could DNA-binding stapled peptides be combined with other gene regulation technologies to create more precise therapeutic interventions?

Common questions

What is a stapled peptide and how does it bind DNA?

A stapled peptide is a short chain of amino acids that has been chemically 'stapled' — typically by a hydrocarbon bridge — to lock it into a helical shape. Many natural proteins use helical regions to grip DNA at specific sequences. By creating stapled peptides that mimic these helical regions of transcription factors, scientists aim to create synthetic molecules that can bind DNA with the same precision as the proteins they imitate.

Why can't we just use small molecule drugs to target DNA?

Small molecules that bind DNA generally cannot distinguish between different DNA sequences very well — they tend to bind broadly rather than at specific gene locations. This lack of selectivity can cause widespread off-target effects. Stapled peptides, by mimicking the DNA-recognition surfaces of natural proteins, have the potential to achieve much higher sequence specificity, targeting only the intended gene regulatory regions.

Read the original research

Double Stranded DNA Binding Stapled Peptides: An Emerging Tool for Transcriptional Regulation.

Chembiochem : a European journal of chemical biology, 24(24), e202300594

View on PubMed ↗Publisher’s paper ↗

Citation

Paquette, André R; Boddy, Christopher N. (2023). Double Stranded DNA Binding Stapled Peptides: An Emerging Tool for Transcriptional Regulation.. Chembiochem : a European journal of chemical biology, 24(24), e202300594. https://doi.org/10.1002/cbic.202300594